THE EFFECTIVENESS OF COMBINED TREATMENT OF DISSEMINATED MALIGNANT PLEURAL MESOTHELIOMA, A DESCRIPTION OF THE CLINICAL CASE

Abstract

Modern approach to the individualization of the management of patients based on the careful observation for the minimal manifestations of the disease, prescription of pemetrexed at the first line of therapy, combination with platinum preparations and antiangiogenic targeted preparation bevazisumab allows control the disease at the advanced stage of pleural mezoteliom and support the good active state of patients during the long time.

Keywords

pleural mesothelioma / chemotherapy / individualization of treatment / stabilization of disease / combined treatment

References

[1] Бычков М.Б., Большакова С.А., Бычков Ю.М. Мезотелиома плевры: современная тактика лечения. Современная онкология. 2005; 7(3): 142-4.

[2] Бычков М.Б., Карпенко Т.Д. Мезотелиома плевры (диагностика, лечение). Сибирский онкологический журнал. 2013; 2: 17-8.

[3] Яблонский П.К., Петров А.С. Злокачественная мезотелиома плевры. Практическая онкология. 2006; 3: 179-86.

[4] Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003; 21(14): 2636-44.

[5] Ceresoli G.L., Zucali P.A., Favaretto A.G. et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J. Clin. Oncol. 2006; 24: 1443-38.

[6] Zalcman G., Mazieres J., Margery J. et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016; 387: 1405-14.

RIGHTS & PERMISSIONS

Eco-Vector